Botulinum Toxin Albumin Complex for Extended Duration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current botulinum toxin formulations for cosmetic and therapeutic use are associated with pain during injection, large subdermal toxin wells, unwanted paralysis, high antigenicity, and immune responses, leading to reduced efficacy and increased treatment frequency.

Innovation Solution

Development of injectable botulinum toxin formulations comprising serotype A botulinum toxin non-covalently associated with a positively charged carrier, such as cationic peptides with protein transduction domains, to enhance diffusion, stability, and duration of action while reducing antigenicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional botulinum toxin formulations are used, then the toxin can be administered for cosmetic and therapeutic purposes, but the formulations cause pain during injection, create large subdermal toxin wells, cause unwanted paralysis, and induce high antigenicity and immune responses

Engineering Contradiction:

ImproveefficacyVSAvoidpain, antigenicity, immune response

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses human albumin as an intermediary carrier to deliver botulinum toxin type A. The albumin forms a complex with the toxin, allowing for reduced antigenicity compared to native toxin complexes, while maintaining therapeutic efficacy. This intermediary approach resolves the contradiction by mediating between the toxin's need to be delivered and the body's immune system that would otherwise recognize and respond to it.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical parameters of the toxin delivery system by using denatured botulinum toxin type A complexed with human albumin. This parameter change (denaturation and complexation) reduces the antigenic properties while preserving the functional activity, thereby reducing immune responses and pain during injection while maintaining therapeutic efficacy.

Inventive Principle:

Principle #35Parameter changes

2Speed

If conventional botulinum toxin formulations are used, then the toxin can be delivered to target tissues, but the toxin diffuses extensively creating large subdermal wells and causing unwanted paralysis

Engineering Contradiction:

ImprovediffusionVSAvoidunwanted paralysis

Core Design Contradiction:

SpeedVSObject-generated harmful factors

Solution Approach 1:

The patent creates a localized delivery system where the botulinum toxin-type A-albumin complex remains concentrated at the injection site rather than diffusing extensively. The complexed form provides local quality control, ensuring the toxin acts primarily where administered, thereby preventing unwanted paralysis in surrounding areas while maintaining effective concentration at the target site.

Inventive Principle:

Principle #3Local quality

3Duration of action of moving object

If conventional botulinum toxin formulations are used, then the toxin can be administered, but the duration of effect is limited requiring frequent treatments

Engineering Contradiction:

Improveduration of effectVSAvoidtreatment frequency

Core Design Contradiction:

Duration of action of moving objectVSProductivity

Solution Approach 1:

The patent employs preliminary complexation of botulinum toxin type A with human albumin before administration. This preliminary action of forming a stable complex enhances the duration of effect in vivo, allowing the toxin to remain active longer at the target site. Consequently, treatment frequency is reduced as the extended duration maintains therapeutic effects for longer periods, improving productivity by reducing the number of required treatments.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulations achieve higher responder rates and extended duration of effect, typically lasting 26 to 40 weeks, with reduced diffusion and antigenicity, allowing for fewer and less painful treatments.

Implementation Method 1

enhance diffusion, stability, and duration of action

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

enhance diffusion, stability, and duration of action

Methodology Applied

Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentUS20250064905A1Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Publication Date: 2025.02.27 REVANCE THERAPEUTICS INC

AI summary

This invention provides injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions embraced by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency, higher responder rates, faster onset of clinical efficacy, and/or improved stability. According to the invention, single treatment of the compositions by injection affords significant clinical responses and at least a 26-week duration of effect in a subject undergoing treatment, as provided by the described treatment methods, as well as still higher responder rates and/or longer duration of effect following subsequent treatments.